Opinion of the Transparency Council – pazopanibum
At its meeting on 30 June 2025, the Transparency Council adopted opinion No. 111/2025 on the appropriateness of transferring the active substance pazopanibum from drug program B.10. “Treatment of patients with kidney cancer (ICD-10 C64)” to the catalog of drugs reimbursed in chemotherapy